Celsion (NASDAQ:CLSN) Stock Price Up 5.9%

Share on StockTwits

Celsion Co. (NASDAQ:CLSN)’s stock price rose 5.9% during mid-day trading on Friday . The company traded as high as $1.83 and last traded at $1.80, approximately 121,358 shares changed hands during mid-day trading. A decline of 4% from the average daily volume of 126,541 shares. The stock had previously closed at $1.70.

CLSN has been the subject of a number of recent research reports. Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a report on Tuesday, July 16th. Brookline Capital Management restated a “buy” rating on shares of Celsion in a research note on Thursday, July 25th. Finally, ValuEngine upgraded Celsion from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.

The company has a debt-to-equity ratio of 0.58, a current ratio of 3.47 and a quick ratio of 4.22. The company has a market capitalization of $36.36 million, a price-to-earnings ratio of -2.65 and a beta of 1.94. The stock has a 50 day simple moving average of $1.75 and a two-hundred day simple moving average of $2.03.

Celsion (NASDAQ:CLSN) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.04. Celsion had a negative return on equity of 53.40% and a negative net margin of 1,489.20%. The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.13 million. Equities research analysts predict that Celsion Co. will post -0.97 EPS for the current year.

A hedge fund recently raised its stake in Celsion stock. BlackRock Inc. raised its holdings in Celsion Co. (NASDAQ:CLSN) by 5.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 146,332 shares of the biotechnology company’s stock after buying an additional 7,070 shares during the period. BlackRock Inc. owned about 0.71% of Celsion worth $267,000 as of its most recent SEC filing. 4.67% of the stock is owned by hedge funds and other institutional investors.

About Celsion (NASDAQ:CLSN)

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Recommended Story: Front-End Load

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.